Pasireotide

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hepatic Cirrhosis

Conditions

Hepatic Cirrhosis, Alcoholism

Trial Timeline

Jul 1, 2008 → —

NCT ID

NCT00698464

About Pasireotide

Pasireotide is a phase 1 stage product being developed by Novartis for Hepatic Cirrhosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00698464. Target conditions include Hepatic Cirrhosis, Alcoholism.

What happened to similar drugs?

3 of 18 similar drugs in Hepatic Cirrhosis were approved

Approved (3) Terminated (5) Active (12)

✅RifaximinBausch HealthApproved

✅Placebo + RifaximinBausch HealthApproved

✅Rifaximin + LactuloseBausch HealthApproved

🔄cisplatin + gemcitabine hydrochlorideEli LillyPhase 3

🔄PhosphatidylcholineSanofiPhase 3

❌oxaliplatin (SR96669) + capecitabine + sorafenibSanofiPhase 3

🔄Givosiran + PlaceboAlnylam PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03103009	Phase 1	Completed	Mar 22, 2017	Dec 22, 2017	Hyperinsulinemic Hypoglycemia
NCT02780882	Phase 2	Withdrawn	Dec 1, 2015	Jun 1, 2019	Ectopic ACTH Syndrome
NCT01617733	Phase 2	Terminated	Mar 1, 2011	Dec 1, 2015	Nelson Syndrome
NCT00698464	Phase 1	Completed	Jul 1, 2008	—	Hepatic Cirrhosis
NCT00434148	Phase 3	Completed	Dec 1, 2006	May 1, 2014	Cushing's Disease
NCT00446082	Phase 1	Completed	Jun 1, 2006	Nov 1, 2013	Carcinoid Tumor
NCT00171730	Phase 2	Completed	Aug 24, 2004	Dec 6, 2013	Acromegaly
NCT00171951	Phase 2	Completed	Aug 13, 2004	Jul 8, 2013	Cushing Disease

Competing Products

20 competing products in Hepatic Cirrhosis

See all competitors

Product	Company	Stage	Hype Score
ITF2357	Biotrial	Phase 1	19
GB1211 + Placebo	Comac Medical	Phase 1/2	18
ACT-541468 25 mg + ACT-541468 25 mg (or 10 mg depending on interim results)	Idorsia	Phase 1	23
Olomorasib	Eli Lilly	Phase 1	29
Simufilam	Cassava Sciences	Phase 1	19
cisplatin + gemcitabine hydrochloride	Eli Lilly	Phase 3	40
exatecan mesylate	Daiichi Sankyo	Phase 2	35
DS-3201b	Daiichi Sankyo	Phase 1	29
Quizartinib	Daiichi Sankyo	Phase 1	29
Quizartinib	Daiichi Sankyo	Phase 1	36
Pexidartinib	Daiichi Sankyo	Phase 1	29
Tivantinib + Tivantinib + Tivantinib + Tivantinib	Daiichi Sankyo	Phase 1	29
Bocidelpar	Astellas Pharma	Phase 1	29
fezolinetant	Astellas Pharma	Phase 1	29
enzalutamide	Astellas Pharma	Phase 1	29
ASP015K	Astellas Pharma	Phase 1	29
ASP2215	Astellas Pharma	Phase 1	29
BPN14770	Shionogi	Phase 1	29
S-217622	Shionogi	Phase 1	29
Lemborexant	Eisai	Phase 1	29